Revolution Medicines Announces Zoldonrasib Showed Manageable Safety, Tolerability Profile In Two Phase 1/2 Clinical Studies; Objective Respo
Revolution Medicines, Inc. (Nasdaq: RVMD ), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for pati